4 September 2024 in RSC Advances
New N-phenylpyrrolamide inhibitors of DNA gyrase were developed with excellent on-target activity and improved antibacterial activity.
8 June 2024 in Journal of Chemical Information and Modeling
The human voltage-gated proton channel, hHV1, is highly expressed in various cell types including macrophages, B lymphocytes, microglia, sperm cells and also in various cancer cells. Overexpression of HV1 has been shown to promote tumor formation by highly metastatic cancer cells, and has been associated with neuroinflammatory diseases, immune response disorders and infertility, suggesting a potential use of hHV1 inhibitors in numerous therapeutic areas. To identify compounds targeting this channel, we performed a structure-based virtual screening on an open structure of the human HV1 channel. Twenty selected virtual screening hits were tested on Chinese hamster ovary (CHO) cells transiently expressing hHV1, with compound 13 showing strong block of the proton current with an IC50 value of 8.5 μM. Biological evaluation of twenty-three additional analogs of 13 led to the discovery of six other compounds that blocked the proton current by more than 50% at 50 μM concentration. This allowed for an investigation of structure-activity relationships. The antiproliferative activity of the selected promising hHV1 inhibitors was investigated in the cell lines MDA-MB-231 and THP-1, where compound 13 inhibited growth with an IC50 value of 9.0 and 8.1 μM, respectively. The identification of a new structural class of HV1 inhibitors contributes to our understanding of the structural requirements for inhibition of this ion channel and opens up the possibility of investigating the role of HV1 inhibitors in various pathological conditions and in cancer therapy.
2 March 2024 in The FEBS Journal
Voltage‐clamp fluorometry (VCF) enables the study of voltage‐sensitive proteins through fluorescent labeling accompanied by ionic current measurements for voltage‐gated ion channels. The heterogeneity of the fluorescent signal represents a significant challenge in VCF. The VCF signal depends on where the cysteine mutation is incorporated, making it difficult to compare data among different mutations and different studies and standardize their interpretation. We have recently shown that the VCF signal originates from quenching amino acids in the vicinity of the attached fluorophores, together with the effect of the lipid microenvironment. Based on these, we performed experiments to test the hypothesis that the VCF signal could be altered by amphiphilic quenching molecules in the cell membrane. Here we show that a phenylalanine‐conjugated flavonoid (4‐oxo‐2‐phenyl‐4H‐chromene‐7‐yl)‐phenylalanine, (later Oxophench) has potent effects on the VCF signals of the Ciona intestinalis HV1 (CiHv1) proton channel. Using spectrofluorimetry, we showed that Oxophench quenches TAMRA (5(6)‐carboxytetramethylrhodamine‐(methane thiosulfonate)) fluorescence. Moreover, Oxophench reduces the baseline fluorescence in oocytes and incorporates into the cell membrane while reducing the membrane fluidity of HEK293 cells. Our model calculations confirmed that Oxophench, a potent membrane‐bound quencher, modifies the VCF signal during conformational changes. These results support our previously published model of VCF signal generation and point out that a change in the VCF signal may not necessarily indicate an altered conformational transition of the investigated protein.
10 December 2024 in Journal of Chemical Information and Modeling
7 August 2026 in Journal of Computer-Aided Molecular Design
Voltage-gated sodium channel Na V 1.7 is a key mediator of electrical excitability and signal transmission in peripheral nociceptors and has emerged as a highly attractive therapeutic target for the development of novel analgesic agents. However, the development of selective Na V 1.7 inhibitors has been characterized by significant challenges, with repeated failures in clinical trials despite encouraging preclinical data. In this study, we developed and validated a series of ligand-based pharmacophore models (LBPMs) that can be useful for the discovery of novel Na V 1.7 inhibitors with improved selectivity profiles. Using the VGSC database as our primary data source, we focused on sulfonamide-based inhibitors targeting the voltage-sensing domain IV (VSD-IV). Validation against active compounds and decoys demonstrated that most models achieved good discrimination performance with high areas under the curve (AUC) and strong enrichment factors. External validation using 22 inhibitors extracted from recent literature confirmed the models’ capability to identify novel Na V 1.7 inhibitors. Virtual screening of 3 million commercially available compounds retrieved promising hits and known inhibitors, with molecular docking studies revealing binding modes consistent with established sulfonamide-based inhibitors. Experimental validation identified one compound with measurable selectivity for Na V 1.7 over Na V 1.5, providing preliminary support for the utility of the developed virtual screening workflow. In parallel, we developed Na V 1.5 LBPMs to assess selectivity profiles and minimize potential cardiotoxic effects. Overall, our findings provide valuable computational tools and structural insights for the rational design of selective Na V 1.7 inhibitors, offering important starting points for developing analgesics with reduced off-target effects.
20 May 2026 in Biomedicine & Pharmacotherapy
The development of new drug molecules targeting voltage-gated ion channels has declined in the last decade, highlighting the need for novel lead compounds with new mechanisms of action. We previously identified NZ-58 as a small-molecule inhibitor of the HV1 proton channel. At 50 μM NZ-58 also potently blocked voltage-gated Na+ and K+ channels, but not the non-voltage-gated ones, suggesting an interaction with the voltage-sensor domains (VSDs). At lower concentrations (0.5-10 μM), it altered gating kinetics with minimal amplitude changes. NZ-58 significantly slowed the current activation kinetics of the channels, as well as the VSD-linked fast inactivation of the NaV1.5 channel, thereby substantially increasing total charge transfer. The loss-of-function Brugada mutant NaV1.5-R1632C was similarly enhanced by NZ-58, but the effect was not present on slowly inactivating KV channels. Gating current measurements confirmed a direct effect on VSD movement. The voltage-dependence of activation and steady-state inactivation were not altered in NaV1.5, but its recovery from inactivation was slowed. NZ-58 was able to bind to the channels in the closed state, not requiring the activated conformation of the VSDs, and it could exert its effects when applied from either side of the membrane. Being non-selective, NZ-58 is not an ideal lead compound for therapeutic ion channel modulation. However, considering that many clinically used ion channel modulators are multi-target "dirty drugs" that still achieve therapeutic benefit, and the unique features of its interactions with voltage-gated channels, we suggest that NZ-58 is worthy of further investigations as a prospective ion channel modulator lead compound.